Skip to main content

Table 3 Treatment-emergent adverse events occurring in ≥ 1.5% patients in the galcanezumab group

From: Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study

Preferred term, n (%) Galcanezumab 120 mg (N = 261) Placebo (N = 259)
Patients with ≥ 1 TEAE 130 (49.8) 112 (43.2)
Injection site pain 19 (7.3) 16 (6.2)
Upper respiratory tract infection 14 (5.4) 13 (5.0)
Injection site pruritis 13 (5.0) 0
Injection site reaction 10 (3.8) 1 (0.4)
Dizziness 9 (3.4) 6 (2.3)
Nasopharyngitis 7 (2.7) 9 (3.5)
Injection site discomfort 6 (2.3) 0
Protein urine present 6 (2.3) 4 (1.5)
Pyrexia 6 (2.3) 3 (1.2)
Abdominal discomfort 5 (1.9) 2 (0.8)
Aspartate aminotransferase increased 5 (1.9) 0
Injection site erythema 5 (1.9) 0
Alanine aminotransferase increased 4 (1.5) 0
Blood creatinine phosphokinase increased 4 (1.5) 0
Diarrhea 4 (1.5) 6 (2.3)
Pruritis 4 (1.5) 2 (0.8)
  1. TEAE Treatment-emergent adverse event, N Number of patients in the analysis population, n number of patients within each specific category